Initial Boost Release of Transforming Growth Factor-β3 and Chondrogenesis by Freeze-Dried Bioactive Polymer Scaffolds
- 270 Downloads
In cartilage regeneration, bio-activated implants are used in stem and progenitor cell-based microfracture cartilage repair procedures. Our aim was to analyze the chondrogenic potential of freeze-dried resorbable polymer-based polyglycolic acid (PGA) scaffolds bio-activated with transforming growth factor-β3 (TGFB3) on human subchondral mesenchymal progenitor cells known from microfracture. Progenitor cells derived from femur heads were cultured in the presence of freeze-dried TGFB3 in high-density pellet culture and in freeze-dried TGFB3-PGA scaffolds for chondrogenic differentiation. Progenitor cell cultures in PGA scaffolds as well as pellet cultures with and without continuous application of TGFB3 served as controls. Release studies showed that freeze-dried TGFB3-PGA scaffolds facilitate a rapid, initial boost-like release of 71.5% of TGFB3 in the first 10 h. Gene expression analysis and histology showed induction of typical chondrogenic markers like type II collagen and formation of cartilaginous tissue in TGFB3-PGA scaffolds seeded with subchondral progenitor cells and in pellet cultures stimulated with freeze-dried TGFB3. Chondrogenic differentiation in freeze-dried TGFB3-PGA scaffolds was comparable to cultures receiving TGFB3 continuously, while non-stimulated controls did not show chondrogenesis during prolonged culture for 14 days. These results suggest that bio-activated, freeze-dried TGFB3-PGA scaffolds have chondrogenic potential and are a promising tool for stem cell-mediated cartilage regeneration.
KeywordsCartilage tissue engineering Cartilage regeneration Resorbable polymer scaffold Polyglycolic acid Chondrocyte differentiation Freeze-drying Growth factor release
The authors are very grateful to Samuel Vetterlein for the excellent technical assistance. JPK, ME and CK are employees of TransTissue Technologies GmbH. TransTissue develops products on the basis of polymer-scaffolds for the regeneration of mesenchymal tissues. This study was supported by the European Union, EU-FP7 program (TissueGEN: HEALTH-F4-2011-278955).
- 2.Alves da Silva, M. L., A. Martins, A. R. Costa-Pinto, V. M. Correlo, P. Sol, M. Bhattacharya, et al. Chondrogenic differentiation of human bone marrow mesenchymal stem cells in chitosan-based scaffolds using a flow-perfusion bioreactor. J. Tissue Eng. Regen. Med. 5:722–732, 2011.Google Scholar
- 8.Cals, F. L., C. A. Hellingman, W. Koevoet, R. J. Baatenburg de Jong, and G. J. van Osch. Effects of transforming growth factor-beta subtypes on in vitro cartilage production and mineralization of human bone marrow stromal-derived mesenchymal stem cells. J. Tissue Eng. Regen. Med. 6:68–76, 2012.PubMedCrossRefGoogle Scholar
- 12.de Girolamo, L., A. Quaglia, C. Bait, M. Cervellin, E. Prospero, and P. Volpi. Modified autologous matrix-induced chondrogenesis (AMIC) for the treatment of a large osteochondral defect in a varus knee: a case report. Knee Surg. Sports Traumatol. Arthrosc. 20:2287–2290, 2012.PubMedCrossRefGoogle Scholar
- 14.Dhollander, A. A., F. De Neve, K. F. Almqvist, R. Verdonk, S. Lambrecht, D. Elewaut, et al. Autologous matrix-induced chondrogenesis combined with platelet-rich plasma gel: technical description and a five pilot patients report. Knee Surg. Sports Traumatol. Arthrosc. 19:536–542, 2011.PubMedCrossRefGoogle Scholar
- 28.Gudas, R., R. J. Kalesinskas, V. Kimtys, E. Stankevicius, V. Toliusis, G. Bernotavicius, et al. A prospective randomized clinical study of mosaic osteochondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint in young athletes. Arthroscopy 21:1066–1075, 2005.PubMedCrossRefGoogle Scholar
- 38.Kopesky, P. W., S. Byun, E. J. Vanderploeg, J. D. Kisiday, D. D. Frisbie, and A. J. Grodzinsky. Sustained delivery of bioactive TGF-beta1 from self-assembling peptide hydrogels induces chondrogenesis of encapsulated bone marrow stromal cells. J. Biomed. Mater. Res. A 102:1275–1285, 2014.PubMedCentralPubMedCrossRefGoogle Scholar
- 39.Kopesky, P. W., E. J. Vanderploeg, J. D. Kisiday, D. D. Frisbie, J. D. Sandy, and A. J. Grodzinsky. Controlled delivery of transforming growth factor beta1 by self-assembling peptide hydrogels induces chondrogenesis of bone marrow stromal cells and modulates Smad2/3 signaling. Tissue Eng. Part A 17:83–92, 2011.PubMedCentralPubMedCrossRefGoogle Scholar
- 51.Patrascu, J. M., J. P. Kruger, H. G. Boss, A. K. Ketzmar, U. Freymann, M. Sittinger, et al. Polyglycolic acid-hyaluronan scaffolds loaded with bone marrow-derived mesenchymal stem cells show chondrogenic differentiation in vitro and cartilage repair in the rabbit model. J. Biomed. Mater. Res. B 101:1310–1320, 2013.CrossRefGoogle Scholar
- 61.Solorio, L. D., C. D. Dhami, P. N. Dang, E. L. Vieregge, and E. Alsberg. Spatiotemporal regulation of chondrogenic differentiation with controlled delivery of transforming growth factor-beta1 from gelatin microspheres in mesenchymal stem cell aggregates. Stem Cells Transl. Med. 1:632–639, 2012.PubMedCentralPubMedCrossRefGoogle Scholar
- 65.Stickings, P., P. Rigsby, K. H. Buchheit, and D. Sesardic. Calibration of European pharmacopoeia biological reference preparation for diphtheria vaccine (adsorbed) batch 4. Pharmeur. Bio. Sci. Notes 1–9:2009, 2009.Google Scholar